Search Results

Innovative Medicine

November 3, 2016

Janssen to Present Data Across Broad Rheumatology Portfolio and Immunology Pipeline at the 2016 American College of Rheumatology Meeting

Twenty-Eight Janssen Data Presentations Demonstrate Commitment to Innovation in Rheumatology

Innovative Medicine

December 12, 2013

FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed-Dose Combination Therapy for Type 2 Diabetes

Innovative Medicine

February 21, 2014

Janssen Initiates CREDENCE Study in Patients with Type 2 Diabetes and Diabetic Nephropathy

Trial Seeks to Examine the Effects of INVOKANA® on the Progression of Diabetic Nephropathy

Financial

October 16, 2012

Johnson & Johnson Reports 2012 Third-Quarter Results

Sales of $17.1 Billion increased 6.5% Versus 2011 Third Quarter; Third-Quarter EPS was $1.05Excluding Special Items, 2012 Third-Quarter EPS of $1.25 increased 0.8%*

January 22, 2013

Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results

2012 Fourth-Quarter Sales of $17.6 Billion increased 8.0%; EPS was $0.912012 Full-Year Sales of $67.2 Billion increased 3.4%; Full-Year EPS was $3.86Excluding Special Items, 2012 Fourth-Quarter EPS was $1.19, an increase of 5.3%*And 2012 Full-Year EPS was $5.10, an increase of 2.0%*

Innovative Medicine

May 16, 2013

SIMPONI® (GOLIMUMAB) Receives FDA Approval For Ulcerative Colitis

First and Only Subcutaneous Biologic Treatment Approved to Induce and Maintain Clinical Response and Improve Endoscopic Appearance of the Mucosa During Induction

Innovative Medicine

September 9, 2011